Have a personal or library account? Click to login
Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs Cover

Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs

By: K Prso,  N Zidekova,  M Dohal,  I Porvaznik,  M Prso,  M Kertys and  J Mokry  
Open Access
|Aug 2020

Authors

K Prso

prso2@uniba.sk

Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia

N Zidekova

Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia

M Dohal

Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia

I Porvaznik

Department of Clinical Microbiology, National Institute for Tuberculosis, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Slovakia
Faculty of Health, Catholic University, Ružomberok, Slovakia

M Prso

Clinic of Children and Adolescents, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, and Martin University Hospital, Martin

M Kertys

Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia

J Mokry

Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Martin, Slovakia
DOI: https://doi.org/10.2478/acm-2020-0006 | Journal eISSN: 1338-4139 | Journal ISSN: 1335-8421
Language: English
Page range: 45 - 55
Submitted on: Apr 29, 2020
|
Accepted on: May 28, 2020
|
Published on: Aug 20, 2020
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 3 issues per year

© 2020 K Prso, N Zidekova, M Dohal, I Porvaznik, M Prso, M Kertys, J Mokry, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.